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ABSTRACT
Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory disorders involving obstruc-
tive airway defects. There have been many discussions on their similarities and differences. Although airflow
limitation expressed as forced expiratory volume in one second (FEV1) has been considered to be the main di-
agnostic assessment in both diseases, it does not reflect the functional impairment imparted to the patients by
these diseases. Therefore, multidimensional approaches using multiple measurements in assessing disease
control or severity have been recommended, and multiple endpoints in addition to FEV1 have been set recently
in clinical trials so as not to miss the overall effects. In particular, as improving symptoms and health status as
well as pulmonary function are important goals in the management of asthma and COPD, some patient-
reported measurements such as health-related quality of life or dyspnea should be included. Nonetheless,
there have been few reviews on the long-term clinical course comparing asthma and COPD as predicted by
measurements other than airflow limitation. Here, we therefore analyzed and compared longitudinal changes in
both physiological measurements and patient-reported measurements in asthma and COPD. Although both
diseases showed similar long-term progressive airflow limitation similarly despite guideline-based therapies,
disease progression was different in asthma and COPD. In asthma, patient-reported assessments of health
status, disability and psychological status remained clinically stable over time, in contrast to the significant dete-
rioration of these parameters in COPD. Thus, because a single measurement of airflow limitation is insufficient
to monitor these diseases, multidimensional analyses are important not only for disease control but also for un-
derstanding disease progression in asthma and COPD.
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INTRODUCTION
Asthma and chronic obstructive pulmonary disease
(COPD) are the two most common respiratory condi-
tions, and have overlapping disease characteristics.
At about 45 years ago, these two diseases were con-
sidered to belong to the same spectrum of syn-
dromes causing airflow limitation.1 However, pres-
ently, there is an increasing realization that they
should be differentiated from each other, although
they can coexist.2 This is not only because their eti-
ological mechanisms differ but also because pharma-
cotherapeutic strategies depend on the diagnosis.3 In-
haled corticosteroids (ICSs) are the mainstay for the
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Table 1 Multidimensional analysis of asthma control
Asthma symptoms/reliever usePulmonary function
Health status or health-related quality of lifeSpirometry
Functional status or disabilityPeak expiratory flow monitoring
Asthma exacerbationsMinimaly invasive markers
Unscheduled health care utilizationAirway hyperesponsiveness
Use of additional or emergency medicationFractionated exhaled nitric oxide
Treatment adherence and side-efectsSputum eosinophils
treatment of asthma, by reducing airway inflamma-
tion and hyperresponsiveness, and, in general, with
dose reduction as asthma severity decreases. In pa-
tients with asthma, bronchodilators are used when
anti-inflammatory therapy to prevent episodes of
bronchoconstriction fails. In contrast, bronchodila-
tors are the fundamental therapy for symptomatic pa-
tients with COPD, and high-dose ICS treatment is re-
served for use with severe COPD patients who have
frequent exacerbations.
Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) guidelines2 are predicated on the fact
that asthma and COPD are inflammatory diseases
causing airflow limitation through an interaction in-
volving different sensitizing agents, different cell
populations in the airway inflammatory process, and
different degrees of reversibility. These two diseases
show similarities, transitions and substantial differ-
ences, and have been discussed extensively from
various perspectives also in this journal.3-7 However,
many features of these diseases including pathogene-
sis and progression are not fully understood.8 Re-
garding the long-term clinical course, the GOLD2 de-
fines COPD as being characterized by progressive
airflow limitation that is not fully reversible. In
asthma, although it is not clearly classified as a pro-
gressive disorder, inflammation progresses and af-
fects lung mechanics, possibly causing irreversible
airflow limitation as a consequence of airway remod-
eling in the long run.9
However, in the management of patients with
asthma and COPD, it is indicated that monitoring air-
flow limitation alone may miss the overall effects of
the disease.10,11 Systemic effects as well as local lung
consequences are also reported in both diseases.12,13
Therefore, in analyzing disease progression, a multi-
dimensional approach with multiple parameters is
necessary to assemble a comprehensive picture of
the disease process.8 We have undertaken this ap-
proach in patients with asthma and COPD.14-19 In the
present review, we summarize and compare available
reports on the long-term clinical course of asthma
and COPD in order to assess the similarities and dif-
ferences between these two diseases.
THE NEED FOR MULTIDIMENSIONAL EVALU-
ATION IN ASSESSING DISEASE PROGRESSION
Asthma is characterized by chronic airway inflamma-
tion in which many cell types are involved, particu-
larly mast cells, eosinophils and CD4+T-lympho-
cytes.2 They release various mediators that contrib-
ute to asthma symptoms. Airway remodeling in
asthma is thought to cause persistent airflow limita-
tion over time.9 Long-term research on adult patients
with asthma has shown that forced expiratory volume
in one second (FEV1), the “gold standard” of airflow
limitation indices, decreases more over the years
than in subjects without asthma.20-22 In the interna-
tional asthma guidelines23,24 and the recent joint
statement by the American Thoracic SocietyEuro-
pean Respiratory Society,25 periodic monitoring of
FEV1 is recommended in addition to symptom as-
sessment to objectively measure asthma severity and
risk of adverse events,26 because patients with
asthma frequently have poor subjective perception of
their symptoms or asthma severity.
The ultimate aim of asthma management is to
achieve and maintain control of the disease. Reducing
airway hyperresponsiveness (AHR) in conjunction
with optimizing symptom reduction and lung function
leads to more effective control of asthma while allevi-
ating chronic airway inflammation.27 Thus, monitor-
ing AHR or markers of airway inflammation such as
induced sputum plays a role in the long-term manage-
ment of asthma. However, although tracking FEV1 or
AHR may tell us about the changes in airway inflam-
matory status or some aspects of disease control,
these measurements do not provide data on the func-
tional, social and psychological impairments experi-
enced by patients,10 indicating that they are clearly
not sufficient for understanding the physiological
changes that accompany disease progression. To re-
flect what is important to patients, for example, health
status or health-related quality of life is more depend-
ent on the overall impact of the disease rather than
on a single measurement.28 Indeed, the 2007 National
Asthma Education and Prevention Program Expert
Panel Report 3, Guidelines for the Diagnosis and
Management of Asthma (the 2007 NAEPP guide-
lines) outline specific measures for periodic assess-
ment (1-6 months intervals) and monitoring of con-
trol, including asthma symptoms and quality of life
functional status as well as pulmonary function.24,29
These patients’ own assessments tend to differ from
those made by clinicians.25 Thus, the use of the multi-
dimensional analysis as in Table 1 including patients’
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Allergology International Vol 59, No3, 2010 www.jsaweb.jp 259
perspectives is important to build up a comprehen-
sive picture of the disease process.
Like asthma, COPD is a chronic respiratory dis-
ease characterized by obstructive airway defects. The
decline of FEV1 has traditionally been used to meas-
ure disease progression in COPD.30 The level of
FEV1 was also used as a severity marker, as it was
previously considered the most crucial predictor of
mortality,31 an important outcome in COPD, consid-
ering that this disease is ranked high as a cause of
death worldwide.2 However, after the year 2000, the
situation changed. We have demonstrated that other
measurements of exercise capacity, health status and
dyspnea, all of which include systemic components,
are important mortality predictors independent of
FEV1 in COPD.32-34 This idea has been applied to
multidimensional disease severity grading protocols,
such as the BODE index (including body mass index,
dyspnea, exercise capacity and airflow limitation)35 or
ADO index (including age, dyspnea and airflow limi-
tation).36 Other studies indicated systemic measure-
ments such as the presence of anemia37 or higher C-
reactive protein levels38 are important mortality pre-
dictors. Current guidelines such as the GOLD2 state
that COPD should be considered a systemic disorder
and be evaluated multidimensionally.
DISEASE MONITORING
ICSs are the mainstay for the therapy of chronic
asthma. They improve symptoms, pulmonary func-
tion, AHR and health status. It has been demon-
strated that the time course of improvement of the
different measurements differs after initiating asthma
treatment with ICSs.25,39 For example, based on clini-
cal trials with high-dose ICS,39 the order of improve-
ment is first, night symptoms, then FEV1, next mini-
mum waking peak expiratory flow, day-time symp-
toms, amount of rescue short-acting β-agonist re-
quired, and finally AHR. However, in comparison to
many short-term studies investigating the effects of
drugs such as ICS on various measurements, little in-
formation is available about their long-term changes
after peak improvements in asthma.
In long-term large-scale studies assessing the ef-
fects of medical treatment, multidimensional ap-
proaches have been used in both asthma and COPD.
In the Inhaled Steroid Treatment as Regular Therapy
in Early Asthma (START) study investigating the ef-
fectiveness of early intervention with ICSs on long-
term asthma control,40,41 asthma-related events, use
of additional asthma medications, asthma symptoms,
restriction in daily activities and sleep problems
caused by asthma were measured in addition to the
change in lung function measured as FEV1. In COPD,
large-scale long-term clinical trials lasting 3-4 years to
investigate the effects of ICSs,42-46 the salmeterolflu-
ticasone propionate combination,47,48 or long-acting
anticholinergic agents49,50 have been reported after
1999. Although, at first, the major endpoints for these
studies were the rates of decline in FEV1, other out-
comes such as change in health status, mortality and
the number of exacerbations have also begun to be
assessed as primary or additional endpoints as in the
Towards a Revolution in COPD Health (TORCH)
trial47,48 and the Understanding Potential Long-Term
Impact on Function with Tiotropium (UPLIFT)
trial.49,50 Thus, unlike the traditional measurement of
disease progression using the decline in FEV1,30 in
light of a better understanding of the multidimen-
sional nature of COPD, progression has been meas-
ured by the rate of change of other outcomes. Halpin
and Tashkin have recently reported that surrogate
markers of progression could include those of (a)
pathobiology, (b) physiologic indices, (c) patient-
centered outcomes, and, ultimately, (d) mortality.51
The working group suggested that the definition of
disease modification should be: an improvement in,
or stabilization of, structural or functional parameters
as a result of reduction in the rate of progression of
those parameters occurring while an intervention is
applied and which may persist even if the interven-
tion is withdrawn.51
In the clinical trials investigating the efficacy of
drugs, physicians’ freedom to apply clinical judgment
to change a patient’s medication might be restricted
due to the rigorous study protocols. We therefore
planned a study to reflect routine clinical practice as
closely as possible by permitting individual judgment
to maximize disease control. We recruited 87 con-
secutive patients with stable asthma15,16 and 137 con-
secutive patients with stable COPD,18,19 all of whom
had been regularly treated previously for at least 6
months in order not to assess the abrupt changes just
after the start of treatment. We then evaluated the pa-
tients with asthma multidimensionally every year,
and the COPD patients every 6 months, both over a
period of 5 years. Pulmonary function, health status,
disability and psychological status were assessed in
both diseases, AHR only in asthma, and exercise ca-
pacity only in COPD. Thus, we obtained information
on the multidimensional effects of maintaining
asthma or COPD control over a longer time period
than usually reported.
LONG-TERM CHANGES IN AIRFLOW LIMITA-
TION
Patients with asthma experience an accelerated and
progressive loss of lung function over time.20-22 ICS
improves FEV1 only for a short period. In contrast, al-
though long-term treatment with ICS may be associ-
ated to some degree with a smaller decline in FEV1,
ICS cannot prevent the development of airflow limita-
tion in some cases of asthma.52-55 There are several
possible reasons for this, airway remodeling being
one candidate9 because the effect of ICS on airway re-
modeling is less evident as compared to its beneficial
Oga T et al.
260 Allergology International Vol 59, No3, 2010 www.jsaweb.jp
Table 2 Baseline data and annual changes in clinical measurements over a 5-year clinical course of 87 patients with stable 
asthma and 137 patients with stable COPD
COPDAsthma
Annual changeBaselineAnnual changeBaseline
69 ± 1 50 ± 2 Age, years
-0.025 ± 0.006***1.22 ± 0.04-0.053 ± 0.011***2.25 ± 0.09FEV1, l
  -0.9 ± 0.2**45.9 ± 1.3   -1.1 ± 0.3**81.7 ± 1.9 FEV1, %predicted
  0.07 ± 0.02***1.57 ± 0.07Log (PD20-FEV1), c.u.
  -0.5 ± 0.1***14.8 ± 0.3 Peak V・ o2, ml/min/kg
   1.9 ± 0.3***36.2 ± 1.4   -0.3 ± 0.520.3 ± 1.4 SGRQ total (0-100)
 0.14 ± 0.02***1.1 ± 0.1  0.01 ± 0.020.3 ± 0.1MRC (0-4)
  0.16 ± 0.08*4.7 ± 0.3 -0.04 ± 0.113.4 ± 0.3HADS anxiety (0-21) 
  0.17 ± 0.07*3.9 ± 0.3  0.03 ± 0.093.3 ± 0.3HADS depression (0-21) 
Results are shown as mean ± SE. The numbers in parentheses indicate the theoretical score range. *p < 0.05, **p < 0.001, ***p < 
0.0001. Adapted and modified from references 15, 16, 18 and 19.
effect on airway inflammation.56,57 Nonetheless, to
achieve improvement in airway remodeling after ICS
therapy, early and long-term persistent treatment
seems to be important even in patients with relatively
mild asthma.40,41,57
Regarding COPD, few drugs have been found
which demonstrated statistically significant effects on
pulmonary function decline, although recent reports
suggest that salmeterol plus fluticasone propionate or
tiotropium significantly reduced the rate of decline in
postbronchodilator FEV1 by 16 mlyear and 6 ml
year, respectively, as compared to placebo.48,50 Con-
sistent with the above-mentioned studies, also in our
experience,15,18 FEV1 declined significantly over 5
years in both asthma and COPD despite continued
treatment to control disease (Table 2, Fig. 1).
LONG-TERM CHANGES IN AHR IN ASTHMA
Previous studies indicate that, after the initiation of
ICS treatment, AHR continues to improve slowly over
many months, although lung function and symptoms
improve relatively more quickly. It is thought that
AHR may reflect both airway inflammation and re-
modeling.57 From the long-term point of view, two
studies demonstrated that AHR continued to improve
over a 3-year period in patients who were following
asthma treatment guidelines.14,58 Our study15 added
data on this issue by showing that an improvement in
AHR peaked after approximately 3 years, but slowly
deteriorated thereafter (Table 2, Fig. 1). However, it
must be borne in mind that the time-scale of changes
in the provocative concentrationdose to cause a cer-
tain degree of airway narrowing (e.g. 20% fall in FEV1:
PC20, PD20) in response to ICS therapy can vary with
the challenge test.25 The recent joint statement re-
ferred to above25 promulgates the notion that AHR
should be regarded as an integrative disease marker,
reflecting multiple pathophysiological mechanisms,
and can be used as a predictor of future risk of exac-
erbations and decline in lung function in longitudinal
studies. Thus, long-term treatment of asthma patients
will be needed to ensure and maintain improvement
in AHR even after asthma symptoms have improved.
LONG-TERM CHANGES IN EXERCISE CAPAC-
ITY IN COPD
In patients with COPD, the degree of activity limita-
tion assessed by an accelerometer worsens with dis-
ease progression,59 and reduced exercise capacity
has significant correlations with mortality.33 In our
study,18 exercise capacity measured by peak oxygen
uptake(o2) on progressive cycle ergometry deterio-
rated significantly, which might be even more promi-
nent than FEV1 (Table 2, Fig. 1). Analyses predicting
its decline revealed that the deterioration in ventila-
tory related factors due to impaired respiratory me-
chanics or ventilatory muscle dysfunction played the
most important role.18 Casanova et al. also reported
that exercise capacity measured by 6 minute walking
distance deteriorated over time in patients with
COPD.60 These deteriorations in exercise capacity
were not strongly correlated with the decline in
FEV1, but would lead to a worsening of exertional
dyspnea or health. Therefore, physical inactivity is an
important therapeutic target in COPD, especially with
the increasing attention being paid to pulmonary re-
habilitation in recent guidelines.61
LONG-TERM CHANGES IN HEALTH STATUS
Usually, health status is not correlated with physi-
ological measurements, and represents disease se-
verity other than what is reflected in pulmonary func-
tion in asthma and COPD.62 Health status is a patient-
reported measure that represents the overall impact
of the level of disease control and exacerbations on
quality of life. Thus, in both diseases, it is now used
in addition to pulmonary function to optimize patient
management strategies and to evaluate the effects of
therapeutic interventions.
Bateman et al. reported that in well-controlled
Clinical Courses of Asthma and COPD
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Fig. 1 Longitudinal changes in (A) FEV1, (B) log (PD20-FEV1) and peak 
V
.
 o2, (C) SGRQ score, (D) MRC score, and (E) HADS anxiety score in 44 
asthma patients (left-hand side) and 45 COPD patients (right-hand side) 
who had complete data sets with no missing data. Higher scores on the 
SGRQ, MRC and HADS indicate a worse status. Results are shown as 
mean ± SE. Adapted and modified from references 15, 16, 18 and 19.
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Fig. 2 Two vicious circle theory of air trapping linking pa-
thophysiology and patient-reported outcomes in COPD. 
Adapted and modified from reference 61.
Airflow limitation
Activity limitation
Deconditioning
Increased ventilatory
requirement
Air trapping
Hyperinflation
Tachypnea
(Rapid and shallow)
Dyspnea
Anxiety
Hypoxemia
Poor health
 status
asthma, maximal or near-maximal Asthma Quality of
Life Questionnaire (AQLQ) scores were attainable,
and concluded that guideline-based asthma control is
beneficial, facilitating greater improvements in health
status.28 Our study15 also supports this conclusion by
our finding that the St. George’s Respiratory Ques-
tionnaire (SGRQ) score remains unchanged for 5
years as a result of guideline-based therapy of asthma
patients (Table 2, Fig. 1). Of note, although airflow
limitation progressed over time, health status was
maintained at a high level. Periodic assessment of
health status is recommended in the 2007 NAEPP
guidelines,24 and generic and asthma-specific vali-
dated instruments or simple questions are recom-
mended for ongoing monitoring.29
In contrast, in patients with COPD, previous stud-
ies from the last 2 years,63,64 using generic health
status questionnaires such as the Nottingham Health
Profile, or in patients with mild COPD64,65 did not find
significant changes in health status. However, dis-
ease severity of the enrolled patients, questionnaires
used and study duration seemed to affect the long-
term changes in health status. In the inhaled steroids
in obstructive lung disease (ISOLDE) trial,46 deterio-
ration in health status was demonstrated in moderate
to severe COPD patients over 3 years using the
disease-specific questionnaire of the SGRQ and the
generic one of the Medical Outcomes Study Short
Form 36-Items Health Survey (SF-36). We have also
shown that health status measured by SGRQ and
Chronic Respiratory Disease Questionnaire (CRQ)
deteriorated over 5 years independently of progres-
sion of airflow limitation (Table 2, Fig. 1).19 Recent
trials of new COPD therapies have of course included
the long-term improvement of health status as out-
comes.
LONG-TERM CHANGES IN DISABILITY
Both asthma and COPD can cause disability. Now,
disability includes impairment, activity limitation and
participation restriction.66 In COPD, it is the major
symptom. In contrast, asthma may cause disability
both through dyspnea-induced exercise limitation
and through the effects of the disease or the impact
of the environment on the patients’ ability to partici-
pate in the activities of their choice or play a full role
in their family and society at large. Although there
are no specific respiratory disability questionnaires,
the Medical Research Council (MRC) dyspnea scale
might be the simplest and most popular. Disability
can be measured as a component of health status
questionnaires.66 The activity limitations domain of
the AQLQ or the activity and impacts components of
the SGRQ also reflect disability, as they are con-
cerned with activity limitation and participation due to
diseases.
In our study, the scores on MRC dyspnea scale re-
mained unchanged for 5 years in patients with
asthma (Table 2, Fig. 1). This holds true both in the
activity and impacts components of the SGRQ.15 In
contrast, in the ISOLDE, the disability worsens over
time in COPD using the SGRQ and the SF-36.46 Also
in our study, this was confirmed using the MRC, and
activity and impacts components of the SGRQ in
COPD over 5 years (Table 2, Fig. 1). In our previous
analysis,19 the change in the MRC score was weakly
related to the progression in FEV1 (r [correlation co-
efficient] = -0.37) and exercise capacity (r = -0.35).
Cooper explains this progressing disability of COPD
on the basis of the two vicious circles theory where
air trapping and hyperinflation play a central role
(Fig. 2).61 The first vicious circle results from activity
limitation, leading to deconditioning, then causing in-
creased ventilatory requirement, a significant factor
worsening air trapping and hyperinflation. COPD ex-
acerbations modify this by worsening airflow limita-
tion and causing hyperinflation. The second vicious
circle revolves around increased respiratory rate and
shortened exhalation time, leading to incomplete
lung emptying, i.e. worsened air trapping and hyper-
inflation, exacerbated by anxiety or hypoxemia.
LONG-TERM PROGRESSION IN PSYCHOLOGI-
CAL STATUS
Psychological disturbance such as anxiety and de-
pression are often addressed both in studies of
asthma and COPD.67 They are reported to be signifi-
cantly related to important clinical outcomes such as
mortality or increased health care utilization. We as-
sessed their 5-year longitudinal changes using the
Hospital Anxiety and Depression Scale (HADS). In
asthma, anxiety and depression scores remained un-
changed over 5 years (Table 2, Fig. 1).16 However,
the baseline score significantly predicted subsequent
changes, indicating that, in asthma, the psychological
disturbance may progress not as a result of disease
progression, but rather because of the individual’s
underlying psychological state.
This finding contrasted with the changes in the
Clinical Courses of Asthma and COPD
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HADS scores in COPD,19 where anxiety and depres-
sion scores worsened over time, and were signifi-
cantly associated with changes in health status scores
or dyspnea scores. Psychological disturbance is very
common especially in patients with severe COPD,
and might be relatively easy to assess using validated
questionnaires. These symptoms of anxiety or de-
pression overlap with symptoms of COPD. Thus, pay-
ing attention to this outcome might also have benefi-
cial effects on other aspects of COPD assessment.68
DIFFICULTIES IN LONG-TERM STUDIES
In analyzing long-term studies, how to deal with drop-
outs is a headache. In our long-term studies of
asthma15 and COPD,19 32% and 47% of the patients
failed to attend the last 5-year evaluation. Especially
in COPD, the sickest patients are reported to be the
most likely to withdraw,69 and differing rates of with-
drawal can compromise primary outcomes in some
large drug treatment studies.70 Therefore, in statisti-
cal analyses, including dropout data is necessary so
as not to underestimate the changes in the measure-
ments. We used random effects models and esti-
mated their changes.71,72 However, the dropout rea-
sons are complex, and one statistical method is not
necessarily ideal for all studies, which makes such
long-term studies difficult to perform, analyze and in-
terpret.
Regarding the above-mentioned study-withdrawals,
experiencing exacerbations is one of the main expla-
nations for the differences in dropout rates.73 Exacer-
bations can affect the long-term changes in measure-
ments. Jones created a model of the relationship be-
tween COPD exacerbations and health status decline
based on the ISOLDE data.73,74 That model of health
status changes over time described two types of pa-
tients, one with no exacerbations and one with a sin-
gle exacerbation per year. Failure to recover only a
very small amount of the acute effect was found to
produce the cumulative effect implied by the faster
rate of deterioration that occurs in patients who expe-
rience exacerbations only once per year, rather than
in patients with no exacerbations.74 In addition to ex-
acerbations, comorbidities may affect long-term clini-
cal changes in both asthma and COPD.75 Thus, in
analyzing longitudinal data, how to assess and in-
clude such confounders is also a big problem.
CONCLUSIONS
Here we review and compare multidimensional longi-
tudinal changes in asthma and COPD. We found that,
although asthma and COPD patients both suffer long-
term progressive airflow limitation, overall disease
progression seems to be very different, which high-
lights the differences between the two diseases. How-
ever, these attempts at analyzing and comparing long-
term changes multidimensionally have just begun,
and approaches could be improved in future by inves-
tigating more appropriate parameters or analytical
models, which will clarify the progression of both dis-
eases.
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